ALX Oncology Holdings Inc. (ALXO) has been on a downward spiral lately with significant selling pressure. After declining 30.8% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting w ...

SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that management will participate in the Jefferies Global Healthcare Conference. Details are as follows: Format: Fireside chat with analyst, Michael Yee and 1x1 Investor MeetingsDate: Wednesday, June 5, 2024 Time: 1:00 PM ET Location: New York, NY Webcast link: A ...

ALX Oncology Holdings Inc. (ALXO) closed the last trading session at $15.61, gaining 21.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $21.33 indicates a 36.6% upside potential.The mean estimate comprises six short-term price targets with a standard deviation of $4.59. While the lowest estimate of $14 indicates a 10.3% decline from the current price level, the most optimistic a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share ALXO The Nasdaq Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ...

Exhibit 99.1 ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO, Calif., May 9, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. "We entered the quarter with a great deal of momentum having achiev ...

ALX Oncology Holdings Inc. (ALXO) reported positive results from an ongoing phase I/II investigator-sponsored study of evorpacept, in combination with Roche’s (RHHBY) Rituxan (rituximab) and Bristol Myers’ (BMY) Revlimid (lenalidomide) (R2), to treat indolent and aggressive relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The early to mid-stage study is sponsored and conducted by MD Anderson Cancer Center, which is based in Texas.ALX Oncology announced that, per findings, patients receiving e ...

– Twenty patients with indolent (n=18) and aggressive (n=2) R/R B-NHL received evorpacept plus standard rituximab and lenalidomide ("R2")– Evorpacept plus R2 was well tolerated with a safety profile similar to historical R2– The combination achieved promising initial activity with a best overall response rate ("ORR") of 94% and a complete response rate ("CRR") of 83% in patients with indolent R/R B-NHL (R2 historical CRR benchmark is 34%) SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- ALX O ...

Exhibit 99.1 ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO, Calif., March 7, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update. "This past year proved to be a p ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39386 ALX ONCOLOGY HOLDINGS INC. (Exact name of regis ...

Financial Performance - Total operating expenses for Q3 2023 were $53.3 million, an increase of 45% compared to $36.7 million in Q3 2022[12]. - Net loss for Q3 2023 was $51.0 million, compared to a net loss of $35.3 million in Q3 2022, representing a 44% increase in losses[12]. - The company reported a net loss per share of $1.24 for Q3 2023, compared to $0.87 for Q3 2022[12]. - The net loss for the nine months ended September 30, 2023, was $115,333, compared to a net loss of $92,773 for the same period in 2022, representing a 24.2% increase in losses[17]. - The company incurred a net loss of $115.3 million for the nine months ended September 30, 2023, compared to $92.8 million for the same period in 2022, reflecting a 24% increase in losses[80]. - The company reported net losses of $51.0 million for Q3 2023, compared to $35.3 million for Q3 2022, marking a 44% increase in losses[80]. Research and Development Expenses - Research and development expenses were $45.8 million in Q3 2023, up from $29.4 million in Q3 2022, reflecting a 56% increase[12]. - Research and development expenses for Q3 2023 were $45.8 million, a 56% increase from $29.4 million in Q3 2022[81]. - For the nine months ended September 30, 2023, research and development expenses rose by $26.8 million (37%) compared to the same period in 2022, driven by a $22.3 million increase in clinical and development costs[82]. - Research and development expenses increased by $16.4 million (56%) for the three months ended September 30, 2023, compared to the same period in 2022, primarily due to a $14.7 million increase in clinical and development costs[82]. Cash and Liquidity - Cash, cash equivalents, and restricted cash at the end of the period were $19,650, down from $49,120 at the end of the previous year, reflecting a decrease of 60%[17]. - As of September 30, 2023, the company had cash, cash equivalents, and investments totaling $196.4 million[88]. - The company experienced a net increase in cash, cash equivalents, and restricted cash of $(29.2) million for the nine months ended September 30, 2023, compared to $(314.5) million for the same period in 2022[92]. - The company has borrowed $10.0 million under a Loan Agreement and has access to draw an additional $40.0 million through the end of 2023, with potential further funding of $50.0 million based on milestones[111]. Equity and Stockholder Information - The company issued 290,000 shares under equity incentive plans during the quarter[16]. - As of September 30, 2023, the company had 41,151,819 shares of common stock outstanding, an increase from 40,861,386 shares as of December 31, 2022[43]. - The total stock options issued and outstanding as of September 30, 2023, were 9,114,886, compared to 6,214,107 for the same period in 2022, indicating a 46.0% increase[55]. - The company completed a follow-on public offering on October 10, 2023, issuing 8,663,793 shares of common stock and receiving net proceeds of approximately $59.0 million after expenses[60]. Debt and Liabilities - Total liabilities increased to $51.4 million from $43.0 million at the end of 2022[10]. - The Company entered into a loan agreement for a secured term loan facility of up to $100.0 million, with an initial draw of $10.0 million and access to an additional $40.0 million through the end of 2023[40]. - As of September 30, 2023, the future maturities under the loan agreement total $10.6 million, with $5.2 million due in 2026 and $4.9 million due in 2027[42]. - Interest expense incurred in connection with the loan agreement was $0.3 million for the three months ended September 30, 2023, and $0.8 million for the nine months ended September 30, 2023[40]. Clinical Trials and Product Development - Evorpacept demonstrated a confirmed overall response rate (ORR) of 52% in combination with trastuzumab, ramucirumab, and paclitaxel for advanced gastric/GEJ cancer, compared to 22% for the control group[65]. - The ASPEN-06 trial included 54 randomized patients previously treated with fam-trastuzumab deruxtecan-nxki and checkpoint inhibitors[65]. - The ASPEN-02 trial, evaluating evorpacept in combination with azacitidine for MDS, was terminated due to insufficient activity to support progression to Phase 2 trials[63]. - The company has initiated multiple clinical studies to explore combinations of evorpacept with anti-cancer antibodies and PD-1/PD-L1 immune checkpoint inhibitors[63]. Regulatory and Compliance Risks - The company must successfully complete clinical trials and obtain regulatory approvals to commercialize evorpacept, which is subject to comprehensive regulation by the FDA[113]. - The FDA may require additional data or clinical trials, potentially delaying clinical timelines for product candidates[114]. - The company faces risks related to the COVID-19 pandemic and geopolitical unrest, which could adversely impact its business and clinical trials[108]. - The company is subject to the Foreign Corrupt Practices Act and similar anti-bribery laws, which could result in serious consequences for violations, including criminal liability[134]. Market and Competitive Landscape - The company faces substantial competition from major pharmaceutical and biotechnology companies in developing immuno-oncology therapies[116]. - The company faces significant competition from various firms developing drugs targeting the CD47 pathway, including major players like Gilead Sciences and Pfizer[117]. - The company’s ability to generate revenue is contingent upon successful product development and regulatory approval, which are subject to various risks and uncertainties[120]. Intellectual Property and Patent Risks - The company faces risks related to potential litigation over intellectual property rights, which could result in significant liabilities and distract management[146]. - The company may need to obtain additional intellectual property rights from others to advance its research or allow commercialization of product candidates, which may not be available on reasonable terms[149]. - The company’s intellectual property rights may not provide competitive advantages due to limitations and potential invalidation of patents[148]. Operational and Management Challenges - The company has limited financial and managerial resources, which may lead to missed opportunities in pursuing potentially profitable product candidates[156]. - The company is vulnerable to product liability claims, and existing insurance coverage may not be sufficient to cover all potential liabilities[156]. - The company must effectively manage its information technology and cloud-based systems to avoid disruptions that could adversely affect business operations[156].